スタッフ紹介

教授 豊嶋 崇徳

写真:教授 豊嶋 崇徳
略歴
  • 1980年 鳥取県立米子東高等学校卒業
  • 1986年 九州大学医学部卒業
  • 1992年 唐津赤十字病院 内科
  • 1993年 北九州市立医療センター 内科
  • 1996年 岡山大学第二内科助手
  • 1997年 米国Harvard大学Dana-Farber Cancer Institute研究員
  • 1999年 米国Michigan大学がんセンター研究員
  • 2000年 米国Michigan大学内科ファカルティー
  • 2002年 岡山大学病院 血液・腫瘍・呼吸器・アレルギー内科助手
  • 2004年 九州大学病院 遺伝子・細胞療法部 准教授
  • 2010年 文部科学省 研究振興局 学術調査官併任
  • 2012年 北海道大学大学院 医学研究科 内科学講座 血液内科学 教授
  • 2014年 国際医療部長
  • 2016年 病院長補佐
  • 2016年 HIV診療支援センター長
  • 2017年 造血幹細胞移植連携支援センター部長
  • 2018年 北海道大学病院 検査・輸血部 部長
賞罰
  • 1999年 米国造血細胞移植学会 最高論文賞
所属学会
  • 日本内科学会(評議員、認定医,総合内科専門医,指導医)
  • 日本血液学会(理事,代議員,専門医,指導医)
  • 日本造血細胞移植学会(副理事長、理事,評議員)
  • 日本輸血・細胞治療学会(理事,評議員,認定医)
  • 日本臨床腫瘍学会
  • 日本エイズ学会
  • 日本免疫学会
  • 日本癌学会
  • 日本リンパ網内系学会
  • 日本組織適合性学会
  • 米国血液学会(Abstract Reviewer)
  • 米国造血細胞移植学会(Scientific Organizing Committee)
  • WBMT: Worldwide Network for Blood and Marrow Transplantation (Board, Graft Processing Standing Committee)
  • APBMT: Asian-Pacific Blood and Marrow Transplantation Group (Scientific Committee)
専門領域
  • 血液学,造血細胞移植学,輸血学,免疫学
代表的業績
  1. Teshima T, et al. CNS involvement in ATL. Cancer 1990; 65: 327.
  2. Teshima T, et al. Cytotoxic drugs and cytotoxic drugs/G-CSF mobilization of PBSCs and their use for autografting. Bone Marrow Transplant 1992;10: 215.
  3. Nagafuji K, et al. Hematopoietic progenitor cells from patient with ATL are not infected with HTLV-I. Blood 1993; 82: 2823.
  4. Teshima T, et al. BMT for EBV-associated NK cell-large granular lymphocyte leukemia. Lancet 1996; 372: 1124.
  5. Hill GR, et al. IL-11 promotes T cell polarization and prevents acute GVHD after allogeneic BMT. J Clin Invest 1998; 102: 115.
  6. Teshima T, et al. IL-11 separates GVL effects from GVHD after BMT. J Clin Invest 1999; 104: 317.
  7. Hill GR, et al. Differential roles of IL-1 and TNF-α on GVHD and GVL. J Clin Invest 1999; 104: 459.
  8. Pan L, et al. G-CSF-mobilized allogeneic SCT maintains GVL effects through a perforin dependent pathway while preventing GVHD. Blood 1999; 93: 4071.
  9. Krijanovski O, et al. Keratinocyte growth factor separates GVL effects from GVHD. Blood 1999; 94: 825.
  10. Reddy P, et al. IL-18 regulates acute GVHD by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433.
  11. Cooke K, et al. LPS antagonism reduces GVHD and preserves GVL activity after BMT. J Clin Invest 2001; 107: 1581.
  12. Teshima T, et al. Tumor cell vaccine elicits potent anti-tumor immunity after allogeneic T-cell depleted BMT. Cancer Res 2001;61: 162.
  13. Teshima T, et al. Acute GVHD does not require alloantigen expression on host epithelium. Nature Med 2002; 8: 575.
  14. Ordemann R, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute GVHD. J Clin Invest 2002; 109: 1249.
  15. Teshima T, et al. Flt3 ligand therapy for recipients of allogeneic BMT expands host CD8α+ dendritic cells and reduces acute GVHD. Blood 2002; 99: 1825.
  16. Teshima T, et al. DLI from immunized donors increases tumor vaccine efficacy after allogeneic BMT. Cancer Res 2002; 62: 796.
  17. Reddy P, et al. IL-18 preserves perforin dependent GVL effect after allogeneic BMT. Blood 2002; 100: 3429.
  18. Teshima T, et al. Impaired thymic negative selection causes autoimmune GVHD. Blood 2003; 102: 429.
  19. Reddy P, et al. Pretreatment of donors with IL-18 attenuates acute GVHD via STAT6 and preserves GVL effects. Blood 2003; 101:2877.
  20. Ichiba T, et al. Early changes in gene expression profiles of hepatic GVHD uncovered by ologonucleotide microarrays. Blood 2003; 102: 763.
  21. Maeda Y, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute GVHD. Blood 2005; 105: 2023.
  22. Teshima T, et al. Impact of HLA mismatch on GVHD and graft failure after reduced intensity conditioning allogeneic HSCT from related donors. Br J Haematol 2005; 130: 575.
  23. Matsuoka K, et al. Fetal tolerance to maternal antigens improves the outcome of allogeneic BMT by a CD4+CD25+ T cell-dependent mechanism. Blood 2006; 107: 404.
  24. Sakoda Y, et al. Donor-derived thymic-dependent T cells cause chronic GVHD. Blood 2007; 109:1756.
  25. Koyama M, et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate GVHD as antigen-presenting cells. Blood 2009; 113: 2088.
  26. Aoyama K, et al. Improved outcome of allogeneic BMT due to breast-feeding-induced tolerance to maternal antigens. Blood 2009; 113: 1829.
  27. Asakura S, et al. Alloantigen expression on non-hematopoietic cells reduces GVL effects. J Clin Invest 2010; 120:2370.
  28. Kikushige Y, et al. TIM-3 is a promising target to selectively kill AML stem cells. Cell Stem Cell 2010; 7: 708.
  29. Teshima T: Th1 and Th17 join forces for acute GVHD. Blood 2011; 118:4765
  30. Takashima S, et al. The Wnt agonist R-spondin1 regulates systemic GVHD by protecting intestinal stem cells. J Exp Med 2011; 208:285.
  31. Hashimoto D, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic HSCT. J Exp Med 2011; 208:1069.
  32. Ferrara JL, et al. Regenerating islet-derived 3α is a biomarker of gastrointestinal GVHD. Blood 2011; 118: 6702.
  33. Nishimori H, et al. Synthetic retinoid Am80 ameliorates chronic GVHD by downregulating Th1 and Th17. Blood 2012;119: 285.
  34. Harris AC, et al. Plasma biomarker of loser gastrointestinal and liver acute GVHD. Blood 2012;119:2960.
  35. Eriguchi Y, et al. GVHD disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012; 120: 223.
  36. Kuriyama T, et al. Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood 2012; 120:4058.
  37. 39. Shima T, et al. Quantification of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic stem cell transplantation. Blood 2013; 121:840.
  38. Shimoji S, et al. Evaluating the association between histological manifestations of cord colitis syndrome with GVHD. Bone Marrow Transplant 2013; 48:1249.
  39. Eriguchi Y, et al. Reciprocal expression of enteric antimicrobial proteins in intestinal graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19: 1525.
  40. Aoyama K, et al. Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood 2013; 122:2125.
  41. Shono Y, et al. Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20:495.
  42. Koyama M, et al. Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant 2014; 49:110.
  43. Sugiyama H, et al. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20:183.
  44. Teshima T : JAK inhibitors: a home run for GVHD patients? Blood 2014; 123:3691
  45. Leemhuis T, Padley D, Keever-Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szabolcs P, Bazarbachi A, Koh MB : Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplant 2014; 49:1098
  46. Arai S, Arora M, Teshima T, et al ; Graft-vs-Host Disease Working Committee of the CIBMTR : Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation - A Report from CIBMTR. Biol Blood Marrow Transplant 2015; 21:266
  47. Teshima T :The primacy of IL-6 in IPS? Blood 2015; 125:2320
  48. Uryu H, Hashimoto D, Kato K, Hayase E, Matsuoka S, Ogasawara R, Takahashi S, Maeda Y, Iwasaki H, Miyamoto T, Saijo S, Iwakura Y, Hill GR, Akashi K, Teshima T :α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. Blood 2015 May 7;125(19):3014-3023
  49. Eriguchi Y, Nakamura K, Hashimoto D, Shimoda S, Shimono N, Akashi K, Ayabe T, Teshima T: Decreased secretion of Paneth cell α-defensin in graft-versus-host disease. Transpl Infect Dis. 17(5): 702-706, 2015 Jul 21
  50. Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, Miyamoto T, Akashi K, Taniguchi S, Harada M, Teshima T: Japan Study Group for Cell Therapy and Transplantation: HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 21(9): 1646-1652, 2015 Sep.
  51. Arai Y, Kondo T, Yamazaki H, Takenaka K, Sugita J, Kobayashi T, Ozawa Y, Uchida N, Iwato K, Kobayashi N, Takahashi Y, Ishiyama K, Fukuda T, Ichinohe T, Atsuta Y, Mori T, Teshima T: Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. Haematologica. 2016 May; 101(5): 644-652
  52. Kanaya M, Shibuya K, Hirochika R, Kanemoto M, Ohashi K, Okada M, Wagatsuma Y, Cho Y, Kojima H, Teshima T: Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease. PLoS One. 2016 Jun 3; 11(6):e0154173.
  53. Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T: Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016 Dec; 101(12):1592-1602.
  54. Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T: Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016 Dec; 101(12):1592-1602.
  55. Teshima T, Reddy P, Zeiser R: Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant. 22(1): 11-16, 2016 Jan.
  56. Shimoji S, Hashimoto D, Tsujigiwa H, Miyawaki K, Kato K, Takahashi S, Ogasawara R, Jiromaru T, Iwasaki H, Miyamoto T, Akashi K, Teshima T: Graft-versus-host disease targets ovary and causes female infertility in mice. Blood. 2017 Mar 2;129(9):1216-1225,
  57. Hayase E, Hashimoto D, Nakamura K, Noizat C, Ogasawara R, Takahashi S, Ohigashi H, Yokoi Y, Sugimoto R, Matsuoka S, Ara T, Yokoyama E, Yamakawa T, Ebata K, Kondo T, Hiramine R, Aizawa T, Ogura Y, Hayashi T, Mori H, Kurokawa K, Tomizuka K, Ayabe T, Teshima T: R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. J Exp Med. Dec 4;214(12):3507-3518. 2017
  58. Yamakawa T, Ohigashi H, Hashimoto D, Hayase E, Takahashi S, Miyazaki M, Minomi K, Onozawa M, Niitsu Y, Teshima T: Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. Blood. 2018 Mar 29; 131(13):1476-1485.2018 Jan 23.
  59. Takahashi S, Hashimoto D, Hayase E, Ogasawara R, Ohigashi H, Ara T, Yokoyama E, Ebata K, Matsuoka S, Hill G, Sugita J, Onozawa M, Teshima T: Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood. 2018 Jan 23. [Epub ahead of print]
コメント

情熱にあふれる若者と将来を語りあうのが何より楽しみです。